Olga Oikonomidou

Research in a Nutshell

Dr Oikonomidou’s group is developing non-invasive analyses of breast cancer in order to understand better the breats cancer biology, identify potential therapeutic targets in cancer (early and advanced) and identify early a patient’s response to treatment.

Research Programme

Contact

Olga.Oikonomidou@ed.ac.uk

Collaborations

• Department of Oncology-Pathology, Karolinska Institutet Breast Center, Karolinska University Hospital
• Institute of Biological Chemistry, Biophysics and Bioengineering, Nasmyth Building, Heriot-Watt University
• Centre of Cardiovascular Science, University of Edinburgh

Partners and Funders

• BCI grant (£100,000) September 2019 Co-PI: Genomics of Endocrine Therapy Resistance – Tailoring Treatment using Personalised Genomic Analysis 
• Make2ndsCount (£190,000) June 2019 PI: Identification of biomarkers of response to CDK4/6 inhibitors in cfDNA sequential samples from patients with secondary breast cancer. November 2019 
• CRUK Early Cancer Detection initiative (£475K) Co-Inv: ‘’ Multiplex methylation analysis of cell-free DNA for early cancer diagnosis. February 2018.  
• NIHR National Institute for Health Research £781K (EME) Co-PI: “Cardiac CARE: A multicentre prospective randomised open-label blinded end-point controlled trial of cardiac troponin guided combination angiotensin receptor blockade and beta blocker therapy to prevent cardiac toxicity in anthracycline treated breast cancer patients”, 3.5 years from September 2017.  
• Chief Scientist Office Research Grant (£220,883) Co-PI : Novel sample preparation for improved circulating tumour DNA analysis. 3 years from July 2015. 
• MRC Confidence in Concept Scheme - Translation of Medical Informatics (£60,000) PI: Bioinformatics analysis of the NEO pilot study. 2 years from May 2014. 
• CRUK Grant-Development Fund (£25,000) PI:  for ‘’The NEO study: a study of factors predicting response to neoadjuvant chemotherapy in breast cancer patients’’. April 2014. 
• University of Edinburgh Internal fund (£40,000) Co-PI: the role of Magnetic Resonance Phosphorous Spectroscopy (31P-MRS) in detecting changes in heart function associated with the use of chemotherapy drugs used to treat breast cancer. December 2014.